300+ members

2023-05-08

We have now reached a new milestone regarding memberships. Currently have 300+ members representing 110 different organisations in 25 countries have joined SWEBAGS!

We are so happy that so many have joined our society and hope you all utilize this big gathering of colleagues from all around the world by interacting and sharing news and articles and watching more than 40 hours of webinars from leading colleagues…

Please help us grow further by spreading the word to your colleagues.

New publication: Dopamine Agonist Cotreatment Alters Neuroplasticity and Pharmacology of Levodopa-Induced Dyskinesia.

2023-01-27

Author: Espa E, Song L, Skovgård K, Fanni S, Cenci MA.

Abstract:

Background: Current models of L-DOPA-induced dyskinesia (LID) are obtained by treating dopamine-depleted animals with L-DOPA. However, patients with LID receive combination therapies that often include dopamine agonists. 

Objective: Using 6-hydroxydopamine-lesioned rats as a model, we aimed to establish whether adjunct treatment with the D2/3 agonist ropinirole impacts on patterns of LID-related neuroplasticity and drug responses. 

Methods: Different regimens of L-DOPA monotreatment and L-DOPA-ropinirole cotreatment were compared using measures of hypokinesia and dyskinesia. Striatal expression of ∆FosB and angiogenesis markers were studied immunohistochemically. Antidyskinetic effects of different drug categories were investigated in parallel groups of rats receiving either L-DOPA monotreatment or L-DOPA combined with ropinirole.

Results: We defined chronic regimens of L-DOPA monotreatment and L-DOPA-ropinirole cotreatment inducing overall similar abnormal involuntary movement scores. Compared to the monotreatment group, animals receiving the L-DOPA-ropinirole combination exhibited an overall lower striatal expression of ∆FosB with a distinctive compartmental distribution. The expression of angiogenesis markers and blood-brain barrier hyperpermeability was markedly reduced following L-DOPA-ropinirole cotreatment vs L-DOPA monotreatment. Significant group differences were moreover detected upon comparing the response to candidate antidyskinetic drugs. In particular, compounds modulating D1 receptor signaling had a stronger effect in the L-DOPA-only group, whereas both amantadine and the selective NMDA antagonist MK801 produced a markedly larger antidyskinetic effect in L-DOPA-ropinirole cotreated animals.

Conclusions: Cotreatment with ropinirole altered LID-related neuroplasticity and pharmacological response profiles. The impact of adjuvant dopamine agonist treatment should be taken into consideration when investigating LID mechanisms candidate interventions in both clinical and experimental settings. 

Link: https://pubmed.ncbi.nlm.nih.gov/36656044/

IBAGS 2023

2023-01-12

The abstract submission deadline and early-bird registration time has been prolonged to January 31st 2023.

Honorary Members

2022-12-08

We are happy to announce that Kjell Fuxe and Wolfram Schultz were elected as honorary members of SWEBAGS.

They will give their honorary lecture early 2023 , we will announce the date and time in the event calendar as soon as we have this confirmed.

SWEBAGS Conference 2022

2023-06-28

We are repeating the the success from last year and arranging a One Day Online Conference November 30.

EBRAINS FENS Satellite event

2023-06-28

EBRAINS will arrange a Satellite event @ FENS, Friday July 8, from 8:30AM to 5:30PM CEST at the INSPE, Paris (lunch included).

It will highlight the connections between basic and clinical neuroscience and computational neuroscience. The program is structured around four sessions on why, what, how and where to integrate multi-resolution and multi-scale data for neuroscience research. More info and free registration.